ERBB2 and ductal breast carcinoma in situ: Here, an updated review of existing data on a role of the HER2–TIME crosstalk in DCIS and its potential value in the stratification of the risk of recurrence is presented in the context of the available evidence of the subtype-dependent clinical significance of stromal immune cells in DCIS (summarized in Table 1).